Literature DB >> 6695772

Hemodynamic effects of nifedipine during upright exercise in stable angina pectoris and either normal or severely impaired left ventricular function.

G I Nelson, B Silke, R C Ahuja, S P Verma, M Hussain, S H Taylor.   

Abstract

The immediate effects of sublingual nifedipine (20 mg) were evaluated in 18 men with stable, exercise-related angina pectoris and angiographically confirmed coronary artery obstructions, stratified at the time of left ventricular (LV) angiography according to the degree of LV dysfunction supine at rest (Group 1: n = 9, left ventricular end-diastolic pressure [LVEDP] less than 20 mm Hg; Group 2: n = 9, LVEDP greater than 20 mm Hg). At rest, in the upright posture in both groups, nifedipine reduced the systemic vascular resistance (p less than 0.01). The systemic arterial mean (p less than 0.05) and diastolic (p less than 0.01) pressures were reduced despite an increase in the cardiac output (p less than 0.05). Heart rate was increased only in Group 1 (p less than 0.05). Pulmonary artery occluded pressure was unchanged in both groups. During upright bicycle exercise in all patients, compared to control measurements, systemic arterial pressure (p less than 0.01) and vascular resistance (p less than 0.05) were similarly reduced, while exercise cardiac output response and LV filling pressure did not change after nifedipine. Heart rate was increased in Group 1 (p less than 0.05) and decreased in Group 2 (p less than 0.05). Stroke volume during exercise after nifedipine decreased 1 ml/m2 in Group 1 (p greater than 0.05) and increased 2 ml/m2 in Group 2 (p greater than 0.05) compared to control measurements; the between-group difference in the exercise heart rate and stroke volume responses after nifedipine were significant at the 5% level.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6695772     DOI: 10.1016/0002-9149(84)90011-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

1.  Effects of nifedipine on cardiac function in patients with coronary artery disease evaluated with ambulatory radionuclide monitoring.

Authors:  H Kambara; I H Mohiuddin; N Tamaki; T Fudo; M Hayashi; R Nohara; J Konishi; C Kawai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Immediate and long-term effects of nicardipine, at rest and during exercise, in patients with coronary artery disease.

Authors:  C A Visser; W Jaarsma; G Kan; J J Koolen; K I Lie
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

Review 4.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

5.  Hemodynamic interactions of a new beta blocker, celiprolol, with nifedipine in angina pectoris.

Authors:  B Silke; S P Verma; S Guy
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

6.  Comparison of haemodynamic effects of nifedipine and molsidomine in patients with coronary artery disease.

Authors:  M Kyriakidis; G Vyssoulis; P Sfikakis; C Kyriakidis; C Pitsavos; K Valsamis; V Nomikos; P Toutouzas
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

7.  Modification of pacing-induced alterations in diastolic properties of the regional myocardium by nifedipine in patients with coronary artery disease.

Authors:  H Nonogi; S Sasayama; S Miyazaki; H Asanoi; K Yamanishi; C Kawai; S Eiho; M Kuwahara
Journal:  Heart Vessels       Date:  1985-11       Impact factor: 2.037

Review 8.  The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review.

Authors:  A L Soward; G L Vanhaleweyk; P W Serruys
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.